Biotherapeutics Cell Line Development Market Forecasts To 2024 Biotherapeutics Cell Line Development Market - Glo

Biotherapeutics Cell Line Development Market - Global Industry
Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2022
With the increasing number of recombinant protein therapeutics gaining approval by the U.S. Food
and Drug Administration (FDA) annually, there is an increase in the demand of cell lines for production
of these biotherapeutics. From 2006 to 2011 an average of 15 novel recombinant protein therapeutics
and in 2014, 11 novel recombinant protein therapeutics have been approved by US FDA. About forty-
seven monoclonal antibody products have been approved in the U.S., Europe and other global
markets, of which over 60% were produced in mammalian cell culture. Moreover, the rise in the
geriatric population coupled with prevalence of diseases is one of the major factors driving the demand
for cell line development for biotherapeutics. The increasing demand for monoclonal antibodies across
the globe boosts the market growth. In addition, the increasing number of initiatives taken by the
government of various countries by funding the life science research and development is expected to
propel this market in coming years.
This 80 page report gives readers a comprehensive overview of the Medical Education market Browse
through 16 data tables and 22 figures to unlock the hidden opportunities in this market.
http://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html
The global biotherapeutics cell line development market is segmented by process, by cell line
development option and by geography. The market by process segment has been sub-segmented as
transfection and single cell cloning. The single cell cloning market is further sub-segmented by method
into manual limited dilution cloning, FACS, ClonePix and Others. The market by CLD option is
segmented as In-house, outsource, hybrid and do-it-yourself. The ClonePix accounted for the largest
market share of 37.4% in 2014. Geographically, the market has been studied and estimated for five
regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The market overview section of the report demonstrates major market dynamics such as drivers,
restraints, and opportunities that influence the current and future status of the industry. The market
overview section includes market attractiveness analysis, by geography, to provide a thorough
analysis of the overall competitive scenario in the global biotherapeutics cell line development market.
The market overview section of the report also includes the qualitative and quantitative analysis of the
competitive landscape.
Market share analysis for FACS market is also provided in the market overview section of the report
for 2014 in terms of value (%). The report also provides important recommendations for market players
and new entrants. These recommendations would enable existing market players to expand their
market shares and help new companies to establish their presence in the biotherapeutics cell line
development market across the world. The report concludes with the company profiles section, which
includes key information about major players in the market such as financial overview, business
strategies, and recent developments. Major players in this market are Becton Dickinson & Company
(U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC